

*張凱評醫師

所有發表期刊論文

(1) First or Correspondence Author:

1. **Chang KP**, Huang CC, Li HY, 2000; 35(1): Embedded retropharyngeal foreign body- report of two cases. **J Taiwan Otolaryngol Head Neck Surg.** 71-74.
2. **Chang KP**, Tsang NM, Chen CY, Su JL, Hao SP, 2000; 110: Endoscopic management of skull base osteoradionecrosis. **Laryngoscope.** 1162-1165.
3. **Chang KP**, Li HY, 2001; 36(3): Treatment results of snoring and sleep apnea in children. **J Taiwan Otolaryngol Head Neck Surg.** 148-154.
4. **Chang KP**, Hao SP, Lin SY, Tsao KC, Kuo Tt, Tsai MS, Tsang NM, 2002; 112: A lack of association of p53 mutations and recurrent nasopharyngeal carcinoma refractory to radiotherapy. **Laryngoscope.** 2015-2019. **(NSC 87-2314-B182A-003)**
5. **Chang KP**, Huang TS, Hsu HC, Su SY. 2004; S1(5): Cochlear implantation in a post-irradiated patient for nasopharyngeal carcinoma. **Cochlear Implants International.** 227
6. **Chang KP**, Hao SP, Tsang NM, Ueng SH. 2004; 131(4): Salvage surgery for locally recurrent nasopharyngeal carcinomas -A 10-year experience. **Otolaryngol Head Neck Surg.** 497-502.
7. **Chang KP**, Chen YL, Hao SP, Chen SM. 2005; 132(1): Echo-guided closed drainage for abscesses of the head and neck. **Otolaryngol Head Neck Surg.** 119-124.
8. **Chang KP**, Lee LY, Yeh AR, Dai TS, Hao SP. 2005; 27(11): Endoscopic CO₂ Laser Surgery for an Atypical Carcinoid Tumor of the Epiglottis Masquerading as a Supraglottic Cyst. **Head Neck.** 1004-1007.
9. **Chang KP**, Hao SP, Lin SY, Ueng SH, Pai PC, Tsao KC, Tseng CK, Hseuh C, Hsieh MS, Yu JS, Tsang NM, 2006; 116(4): The 30-bp Deletion of EBV LMP-1 Gene Has

No Effect in Nasopharyngeal Carcinoma. **Laryngoscope**. 541-546.
(NSC92-2314-B-182A-207)

10. Cheng TY, Ueng SH, Chen YL, Chen TM, **Chang KP***. 2006; 29: Oncocytic Schineiderian Papilloma Found in a Recurrent Chronic Paranasal Sinusitis - a Case Report. **Chang Gung Med J**. 336-41. **(Correspondence Author)**
11. Chen MF, Ueng SH, Jung SM, Chen YL, **Chang KP***. 2006; 29: A Type II First Branchial Cleft Cyst Masquerading as an Infected Parotid Warthin's Tumor. **Chang Gung Med J**. 434-8. **(Correspondence Author)**
12. **Chang KP**, Hao SP, Chiu CT, Cheng MH, Chang YL, Lee YS, Wang TH, Tsai CN*. Promoter Polymorphisms of DNMT3B and the Risk of Head and Neck Squamous Cell Carcinoma in Taiwan: A Case-Control Study. **Oral Oncol**. 2007; 43(4): 345-351.
13. **Chang KP**, Hao SP, Tsang NM, Chang YL, Cheng MH, Liu CT, Lee YS, Tsai CL, Lee TJ, Wang TH, Tsai CN*. Gene Expression and Promoter Polymorphisms of DNMT3B in Nasopharyngeal Carcinomas for Taiwanese people: A Case-Control Study. **Oncol Rep**. 2008; 19: 217-222 **(NSC 95-2314-B-182A -105)**
14. Fu CH, Ueng SH, Shao PY, **Chang KP***. Pathology Quiz: Solitary fibrous tumor (SFT) of the submandibular gland. **Arch Otolaryngol Head Neck Surg**. 2008; 134(2): 214-216 **(Correspondence Author)**
15. **Chang KP**, Hsu CL, Chang YL, Tsang NM, Chen CK, Lee TJ, Huang CG, Tsao KC, Chang YS, Yu JS, Hao SP*. Complementary Serum Test of Antibodies to Epstein-Barr Virus Nuclear Antigen-1 and Early Antigen: A Possible Alternative for Primary Screening of Nasopharyngeal Carcinoma. **Oral Oncol**. 2008; 44:784-792. **(NSC92-2314-B-182A-207)**
16. Fu CH, **Chang KP***, Ueng SH, Wu CC, Hao SP. Primary Thyroid-Like Papillary Adenocarcinoma of the Nasopharynx. **Auris Nasus Larynx**. 2008; 35(4): 579-582. **(Correspondence Author)**
17. **Chang KP**, Hao SP, Chang JH, Wu CC, Tsang NM, Lee YS, Hsu CL, Ueng SH, Liao SC, Liu YL, Wei PC, Liang Y, Chang YS, Yu JS*. Macrophage Inflammatory Protein-3 α Is a Novel Serum Marker for Nasopharyngeal Carcinoma Detection

- and Prediction of Treatment Outcomes. **Clin Cancer Res.** 2008; 14(21): 6979-6987. **(NSC94-2314-B-182A-188 & NSC96-2314-B-182A-109-MY3)**
18. Hsin LJ, Fang TJ, **Chang KP***, Fang KH, Tsang NM, Chen YL, Jung SM, Yeh AR, Hao SP. Transoral Endoscopic CO₂ Laser Microsurgery for Early Laryngeal Cancers. **Chang Gung Med J.** 2009; 32: 517-25. **(Correspondence Author)**
19. Fang KH, Kao HK, Cheng MH, Chang YL, Tsang NM, Huang YC, Lee LY, Yu JS, Hao SP, **Chang KP***. 2009: Histological differentiation of primary oral squamous cell carcinomas in betel quid prevalent area. **Otolaryngol Head Neck Surg.** 2009; 141(6): 743-749. **(Correspondence Author)**
20. Tam YY, Li LY, **Chang KP***. Lymphoepithelial Carcinoma of the Nasolacrimal Duct. **Otolaryngol Head Neck Surg.** 2010; 142(1): 144-145. **(Correspondence Author)**
21. **Chang KP**, Kao HK, Liang Y, Cheng MH, Chang YL, Liu SC, Lin YC, Ko TY, Lee YS, Tsai CL, Wang TH, Hao SP*, Tsai CN*. Overexpression of activin A in oral squamous cell carcinoma: association with poor prognosis and tumor progression. **Ann Surg Oncol** 2010; 17(7):1945-56. **(NSC96-2314-B-182A-109-MY3)**
22. **Chang KP**, Wu CC, Chen HC, Chen SJ, Peng PH, Tsang NM, Lee LY, Liu SC, Liang Y, Lee YS, Hao SP, Chang YS, Yu JS*. Identification of Candidate Nasopharyngeal Carcinoma Serum Biomarkers by Cancer Cell Secretome and Tissue Transcriptome Analysis: Potential Usage of Cystatin A for Predicting Nodal Stage and Poor Prognosis. **Proteomics.** 2010; 10: 2644-2660. **(NSC96-2314-B-182A-109-MY3)**
23. **Chang KP**, Kao HK, Yen TC, Chang YL, Liang Y, Liu SC, Lee LY, Chang YL, Kang CJ, Chen IH, Liao CT*, Yu JS*. Overexpression of macrophage inflammatory protein-3alpha in oral cavity squamous cell carcinoma is associated with nodal metastasis. **Oral Oncol.** 2011; 47: 108-113. **(NSC99-2314-B-182A-051-MY3)**
24. Kao HK, Guo LF, Cheng MH, Chen IH, Liao CT, Fang KH, Yu JS, **Chang KP***. Predicting Postoperative Morbidity and Mortality by MELD Score for Patients with Head and Neck Cancer and Liver Cirrhosis. **Head Neck.** 2011; 33: 529-534. **(Correspondence Author)**

25. **Chang KP**, Chang YT, Liao CT, Yen TC, Chen IH, Chang YL, Liu YL, Chang YS, Wu CC*, Yu JS*. Prognostic cytokine markers in peripheral blood for oral cavity squamous cell carcinoma identified by multiplexed immunobead-based profiling. **Clin Chim Acta**. 2011; 412: 184-191.
(NSC99-2314-B-182A-051-MY3)
26. **Chang KP**, Chang YT, Wu CC, Liu YL, Chen MC, Tsang NM, Hsu CL, Chang YS, Yu JS*. Multiplexed immunobead-based profiling of cytokine markers for detection of nasopharyngeal carcinoma and prognosis of patient survival. **Head Neck**. 2011; 33(6): 886-697. **(NSC96-2314-B-182A-109-MY3)**
27. Yu CJ, **Chang KP**, Chang YJ, Hsu CW, Liang Y, Yu JS, Chi LM, Chang YS, Wu CC*. Identification of guanylate-binding protein 1 as a potential oral cancer marker involved in cell invasion using omics-based analysis. **J Proteome Res**. 2011; 10(8):3778-88. **(NSC99-2314-B-182A-051-MY3) (Equal contribution)**
28. **Chang KP**, Yu JS, Chien KY, Lee CW, Liang Y, Liao CT, Yen TC, Lee LY, Huang LL, Liu SC, Chang YS, Chi LM*. Identification of PRDX4 and P4HA2 as metastasis-associated proteins in oral cavity squamous cell carcinoma by comparative tissue proteomics of microdissected specimens using iTRAQ technology. **J Proteome Res**. 2011; 10(11):4935-47.
(NSC99-2314-B-182A-051-MY3)
29. **Chang KP***, Tsang NM, Liao CT, Hsu CL, Chang MJ, Lo CW, Chang SC, Ng SH, Wang HM, Yen TC. Prognostic significant of 18F-FDG PET parameters and plasma EBV DNA load in patients with nasopharyngeal carcinoma. **J Nucl Med**. 2012; 53(1): 21-28. **(NSC99-2314-B-182A-051-MY3) (Correspondence Author)**
30. Hsu HH, Lee LY, **Chang KP***. Pathology Quiz: Osteolipoma of the buccal space. **Arch Otolaryngol Head Neck Surg**. 2012; 138(1):97-98. **(Correspondence Author)**
31. Du CJ, Fu CH, Ng SH, **Chang KP***. Tuberculous arthritis of the temporomandibular joint. **Arch Otolaryngol Head Neck Surg**. 2012; 138(2):197-198. **(Correspondence Author)**

32. Wu CS, Chang KP*, Chen LC, Chen CC, Liang Y, Hseuh C, Chang YS*. Heterogeneous Ribonucleoprotein K and Thymidine Phosphorylase Are Independent Prognostic and Therapeutic Markers for Oral Squamous Cell Carcinoma. **Oral Oncol.** 2012; 48(6):516-22. (NSC99-2314-B-182A-051-MY3) **(Equal Contribution as First and Correspondence Author)**
33. Kao HK, Chen WF, Chen CH, Shyu VB, Cheng MH, **Chang KP***. The Roles of Albumin Levels in Head and Neck Cancer Patients with Liver Cirrhosis Undergoing Tumor Ablation and Microsurgical Free Tissue Transfer. **PLoS One.** 2012; 7(12): e52678. **(Correspondence Author)**
34. Tam YY, Chen CK, **Chang KP***. Sphenothmoidal inverted papilloma causing ipsilateral abducens nerve palsy. **Otolaryngol Head Neck Surg.** 2013; 148(4):703-4. **(Correspondence Author)**
35. **Chang KP**, Kao HK, Wu CC, Fang KH, Chang YL, Huang YC, Liu SC, Cheng MH*. Pretreatment of interleukin-6 serum levels are associated with patient survival for oral cavity squamous cell carcinoma. **Otolaryngol Head Neck Surg.** 2013; 148: 786-791. (NSC99-2314-B-182A-051-MY3)
36. **Chang KP**, Wu CC, Fang KH, Tsai CY, Chang YL, Liu SC, Kao HK*. Serum levels of chemokine (C-X-C motif) ligand 9 (CXCL9) are associated with tumor progression and treatment outcome in patients with oral cavity squamous cell carcinoma. **Oral Oncol.** 2013; 49(8): 802-807. (NSC99-2314-B-182A-051-MY3)
37. **Chang KP**, Wang CA, Kao HK, Ying L, Liu SC, Huang LL, Hseuh C, Hsieh YJ, Chien KY, Chang YS, Yu JS, Chi LM*. Overexpression of caldesmon is associated with nodal metastasis and poorer prognosis in oral cavity squamous cell carcinomas. **Cancer.** 2013; 119: 4003-11. (NSC99-2314-B-182A-051-MY3)
38. Hsin LJ, Kao HK, Chen IH, Tsang NM, Hsu CL, Liu SC, Chang YS, **Chang KP***. Serum CXCL9 levels are associated with tumor progression and treatment outcome in patients with nasopharyngeal carcinoma. **PLoS One.** 2013; 8(11): e80052. **(Correspondence Author)**

39. Lin CK, Hsu HH, Lee LY, **Chang KP***. Nasopharyngeal hemartoma. **J Taiwan Otolaryngol Head Neck Surg.** 2013; 48:319-324. **(Correspondence Author)**
40. Fang KH, Kao HK, Chi LM, Liang Y, Liu SC, Hseuh C, Liao CT, Yen CT, Yu JS, **Chang KP***. Overexpression of BST2 is associated with nodal metastasis and poorer prognosis in oral cavity cancer. **Laryngoscope.** 2014; 124(9):E354-60. (SCI) **(NSC102-2628-B-182-015-MY3) (Correspondence Author)**
41. Hsu CW, Yu JS, Peng PH, Liu SC; Chang YS, **Chang KP***, Wu CC*. Secretome profiling of primary cells reveals that THBS2 is a salivary biomarker of oral cavity squamous cell carcinoma. **J Proteome Res.** 2014; 13(11): 4796-807. (SCI) **(NSC102-2628-B-182-015-MY3) (Correspondence Author)**
42. Fanzio P, **Chang KP**, Chen HH, Hsu HH, Vijay G, Solari M, Kao HK*. Plate exposure after anterolateral thigh free flap reconstruction in head and neck patients with composite mandibular defects. **Ann Surg Oncol.** 22(9): 3055-60. (SCI) **(Equal contribution)**
43. **Chang KP**, Lin SJ, Liu SC, Yi JS, Chien KY, Chi LM, Kao HK, Liang Y, Lin YT, Chang YS, Yu JS*. Low-molecular-mass secretome profiling identifies HMGA2 and MIF as prognostic biomarkers for oral cavity squamous cell carcinomas. **Sci Rep.** 2015; 5: 11689. (SCI)
44. Adel M, Kao HK, Hsu CL, Huang JJ, Lee LY, Huang YL, Browne T, Tsang NM, Chang YL, **Chang KP***. Evaluation of Lymphatic and Vascular Invasion in Relation to Clinicopathological Factors and Treatment Outcome in Oral Cavity Squamous Cell Carcinoma. **Medicine.** 2015 (In Press, SCI)
45. Wu CC, Chu HW, Hsu CW, **Chang KP***, Liu HP*. Saliva proteome profiling reveals potential salivary biomarkers for detection of oral cavity squamous cell carcinoma. **Proteomics.** 2015 (In Press, SCI,) **(NSC102-2628-B-182-015-MY3) (Correspondence Author)**

(2) Co-author:

46. Hao SP, Tsang NM, **Chang KP**, 2001; 111: Differentiation of recurrent nasopharyngeal carcinoma and skull base osteoradionecrosis by Epstein-Barr virus-derived latent membrane protein-1 gene. **Laryngoscope**. 650-652.
47. Li HY, Lo LJ, Chen KS, Wong KS, **Chang KP**, 2002 Aug 1;65(1): Robin sequence: review of treatment modalities for airway obstruction in 110 cases. **Int J Pediatr Otorhinolaryngol**. 45-51.
48. Dai TS, Hao SP, **Chang KP**, Pan WL, Yeh HC, Tsang NM. 2003; 128: Complications of mandibulotomy: midline versus paramidline. **Otolaryngol Head Neck Surg**. 137-141.
49. Pan WL, Hao SP, Lin YS, **Chang KP**, Su JL. 2003; 113: The anatomical basis of mandibulotomy: midline versus paramidline. **Laryngoscope**. 377-380.
50. Hao SP, Tsang NM, Chen YL, **Chang KP**, Su JL. 2003; 39: Detection of LMP-1 gene in middle ear effusion of NPC. **Oral Oncology**. 296-300.
51. Hao SP, Tsang NM, **Chang KP**. 2003; 97: Screening nasopharyngeal carcinoma by detection of LMP-1 gene from nasopharyngeal swab. **Cancer**. 1909-13. **(NSC90-2314-B-182A-120)**
52. Tsang NM, **Chang KP**, Lin SY, Hao SP, Tseng CK, Kuo Tt, Tsai MS, Chung TC. 2003; 113: Detection of Epstein-Barr Virus-derived latent membrane protein – 1 in various head and neck cancers: Is it specific for NPC? **Laryngoscope**. 1050-1054. **(NSC89-2314-B-182A-089-M08)**
53. Hao SP, Tsang NM, **Chang KP**, Ueng SH. 2004; 131(5): Molecular diagnosis of nasopharyngeal carcinoma- detecting LMP-1 and EBNA by nasopharyngeal swab. **Otolaryngol Head Neck Surg**. 657-660.
54. Hao SP, Tsang NM, **Chang KP**. 2004; 114(11): Monitoring Tumor Recurrence with Nasopharyngeal Swab and LMP-1 and EBNA-1 Gene Detection in Treated Patients of NPC. **Laryngoscope**. 2027- 2030. **(NSC93-2314-B-182A-047)**

55. Wu CC, Chien KY, Tsang NM, **Chang KP**, Hao SP, Tsao CH, Chang YS, Yu JS. 2005; 5(12): Cancer cell- Secreted Proteomes as a Basis for Searching Potential Tumor Markers - Nasopharyngeal Carcinoma as a Model. **Proteomics**. 3173-3182. **(NSC91-2320-B-182-038 & NSC92-2320- B-182-047)**
56. Lin SY, **Chang KP**, Hsiesh MS, Hao SP, Tseng CK, Pai PC, Chang FT, Tsang NM. 2005; 63(5): The time frame for Epstein-Barr virus Latent Membrane Protein-1 (EBV LMP-1) to disappear after initiation of primary radiotherapy is an independently significant prognostic factor predicting local control for the patients with nasopharyngeal carcinoma. **Int J Radiat Oncol Biol Phys**. 1339-1346. **NSC 89-2314-B-182A-089-M08 & NSC 93-2314-B-182A-128)**
57. Yazar S, Cheng MH, Wei FC, Hao SP, **Chang KP**. 2006; 28:Osteomyocutaneous Peroneal Artery Perforator Flap for Reconstruction of Composite Maxillary Defects. **Head Neck**. 297-304.
58. Hao SP, Tsang NM, **Chang KP**, Chen CK, Huang SS. 2006; 116: Treatment of Squamous Cell Carcinoma of the Retromolar Trigone. **Laryngoscope**. 916-920.
59. Huang HC, **Chang KP**, Chen TM*, Wu KF, Ueng SH. Renal cell carcinoma metastasis in the head and neck. **Chang Gung Med J**. 2006; 29(4 Suppl): 59-65.
60. Liang CW, Li HY, **Chang KP**, Chen CK, Chen YL*. HIV infection initially presenting as sinonasal Burkitt's lymphoma. **Am J Otolaryngol**. 2006; 27: 433-435.
61. Pai PC, Tseng CK, Chuang CC, Wei KC, Hao SP, Hsueh C, **Chang KP**, Tsang NM*. Polymorphism of C-terminal activation region 2 of Epstein-Barr virus latent membrane protein 1 in predicting distant failure and post-metastatic survival in patients with nasopharyngeal carcinoma. **Head Neck**. 2007; 29: 109-119.
62. Fu CH, **Chang KP**, Lee TJ*. The difference in anatomical and invasive characteristics between primary and secondary paranasal sinus mucoceles. **Otolaryngol Head Neck Surg**. 2007; 136: 621-625.

63. Hao SP*, Tsang NM, **Chang KP**, Chen CK, Chao WC. Osteoradionecrosis of External Auditory Canal in Nasopharyngeal Carcinoma. **Chang Gung Med J.** 2007; 30: 116-121.
64. Chen YA, **Chang KP**, Lin YS, Hao SP*. A randomized, double-blind, parallel-group study to compare the efficacy and safety of a once-daily loratadine-pseudoephedrine combination with that of a twice-daily loratadine-pseudoephedrine combination in the treatment of allergic rhinitis. **Eur Arch Otorhinolaryngol.** 2007; 264(9): 1019-25.
65. Tse KP, NM Tsang, Chen KD, Liang Y, Li HP, Hseuh C, **Chang KP**, Yu JS, Hao SP, Hsieh, LL, Chang YS*. 2007;13: Single Nucleotide Polymorphism at -2518 of the MCP-1 Gene Regulatory Region is Associated with Metastasis of Nasopharyngeal Carcinoma. **Clin Cancer Res.** 6320-6326. **(NSC 93-2314-B-182A-128)**
66. Hao SP*, Tsang NM, **Chang KP**, Hsu YS, Chen CK, Fang KH. Nasopharyngectomy for recurrent nasopharyngeal carcinoma: a review of 53 patients and prognostic factors. **Acta Oto- Laryngol.** 2008;128(4): 473-81
67. Chen LC, Hseuh C, Tsang NM, Liang Y, **Chang KP**, Hao SP, Yu JS, Chang YS*. Heterogeneous Ribonucleoprotein K and Thymidine Phosphorylase are Independent Prognostic and Therapeutic Markers for Nasopharyngeal Carcinoma. **Clin Cancer Res.** 2008; 14: 3807-3813. **(NSC 93-2314-B-182A-128)**
68. Wu CC, Peng PH, Chang YT, Huang YS, **Chang KP**, Hao SP, Tsang NM, Yeh CT, Chang YS, Yu JS*. Identification of potential serum markers for nasopharyngeal carcinoma from a xenografted mouse model using Cy dye labeling combined with three-dimensional fractionation. **Proteomics.** 2008; 8 (17): 3605-3620.
69. Cheng CC, **Chang KP**. How we do it: management of tracheobronchial foreign bodies in children. **Clin Otolaryngol.** 2008; 33: 502-503.
70. Cheng MH*, Saint-Cyr M, Ali RS, **Chang KP**, Hao SP, Wei FC. Osteomyocutaneous peroneal artery-based combined flap for reconstruction of composite and en bloc mandibular defects. **Head Neck.** 2009; 31: 361-370.

71. Lee TJ, Huang CC, Chen YW, **Chang KP**, Fu CH, Chang PH*. Medially originated inverted papilloma. **Otolaryngol Head Neck Surg.** 2009; 140(3): 324-9 .
72. Chen HC, Chen GH, Chen YS, Liao WL, Liu CY, **Chang KP**, Chang YS, Chen SJ*. MicroRNA Deregulation and Pathway Alterations in Nasopharyngeal Carcinoma. **B J Cancer.** 2009; 100: 1002-1011.
73. Chi LM, Lee CW, **Chang KP**, Hao SP, Lee HM, Liang Y, Hsueh C, Yu CJ, Lee IN, Chang YJ, Lee SY, Yeh YM, Chang YS, Chien KY, Yu JS. Enhanced interferon signaling pathway in oral cancer revealed by quantitative proteome analysis of microdissected specimens using ¹⁶O/¹⁸O labeling and integrated 2DLC-ESI-MALDI tandem MS. **Mol Cell Proteomics.** 2009; 8(7): 1453-74.
74. Tse KP, Su WH, **Chang KP**, Tsang NM, Yu CJ, Tang P, See LC, Hsueh C, Yang ML, Hao SP, Li HY, Wang MH, Liao LP, Chen LC, Lin SR, Jorgensen TJ, Chang YS, Shugart YY. Genome-wide association study reveals multiple nasopharyngeal carcinoma-associated loci within the HLA region at chromosome 6p21.3. **Am J Hum Genet.** 2009; 85(2): 194-203.
75. Lee LY, **Chang KP**, Hsu CL, Chen TC, Kuo TT*. Small-Cell Neuroendocrine Carcinoma of the Nasopharynx: Report of a Rare Case Lacking Association with Epstein-Barr Virus. **Int J Surg Path.** 2011; 19(2):199-202.
76. Kao HK, **Chang KP**, Ching WC, Tsao CK, Chen HC, Cheng MH*, Wei FC. The Impacts of Liver Cirrhosis on Head and Neck Cancer Patients Undergoing Microsurgical Free Tissue Transfer: An Evaluation of Flap Outcome and Flap-Related Complications. **Oral Oncol.** 2009; 45: 1058-1062.
77. Kao HK, **Chang KP**, Cheng MH*, Wei FC. Comparison of Radial Forearm Flap and Medial Sural Artery Perforator Flap for Head and Neck Reconstruction. **Plast Reconstr Surg.** 2009; 124(4): 1125-1132.
78. Chang YH, Wu CC, **Chang KP**, Yu JS, Chang YC, Liao PC*. Cell secretome analysis using hollow fiber culture system leads to the discovery of CLIC1

- protein as a novel plasma marker for nasopharyngeal carcinoma. **J Proteome Res** 2009; 8(12):5465-74.
79. Kao HK, **Chang KP**, Ching WC, Tsao CK, Cheng MH*, Wei FC. Postoperative Morbidity and Mortality after Surgical Resection Followed by Microsurgical Free Tissue Transfer for Head and Neck Cancers in Patients with Liver Cirrhosis. **Ann Surg Oncol** 2010; 17(2):536-43.
80. Kao HK, **Chang KP**, Chen YA, Wei FC, Cheng MH*. Anatomical Basis and Versatile Application of Free Medial Sural Artery Perforator Flap for Head and Neck Reconstruction. **Plast Reconstr Surg**. 2010; 125(4):1135-45.
81. Wu CC, Hsu CW, Chen CD, Yu CJ, **Chang KP**, Tai DI, Liu HP, Su WH, Chang YS, Yu JS*. Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas. **Mol Cell Proteomics**. 2010; 9(6):1100-17.
82. Hsueh C*, Chang YS, Tseng NM, Liao CT, Hsueh S, Chang JH, Wu IC, **Chang KP**. Expression pattern and prognostic significance of claudins 1, 4, and 7 in nasopharyngeal carcinoma. **Hum Pathol**. 2010; 41(7):944-50.
83. Ng SH*, Chan SC, Yen TC, Liao CT, Chang JT, Ko SF, Wang HM, Lin CY, **Chang KP**, Lin YC. Comprehensive imaging of residual/recurrent nasopharyngeal carcinoma using whole-body MRI at 3 T compared with FDG-PET-CT. **Eur Radiol**. 2010; 20(9):2229-40.
84. Chen SJ, Chen GH, Chen YH, Liu CY, **Chang KP**, Chang YS, Chen HC. Characterization of Epstein-Barr virus miRNAome in nasopharyngeal carcinoma by deep sequencing. **PLoS One**. 2010;5(9). pii: e12745.
85. Chan WH, **Chang KP**, Yang SW, Yao TC, Ko TY, Lee YS, Tsai CL, Tsai CN*. Transcriptional repression of DLEC1 associated with depth of tumor invasion in oral squamous cell carcinoma. **Oral Oncol**. 2010; 46: 874-879. **(NSC99-2314 -B-182A-051-MY3)**
86. Peng PH, Wu CC*, Liu SC, **Chang KP**, Chen CD, Chang YT, Hsu CW, Chang YS, Yu JS*. Quantitative plasma proteome analysis reveals aberrant levels of blood coagulation-related proteins in nasopharyngeal carcinoma. **J Proteomics**.

2011; 74(5):744-757.

87. Ng SH*, Chan SC, Yen TC, Liao CT, Lin CY, Tung-Chieh Chang J, Ko SF, Wang HM, **Chang KP**, Fan KH. PET/CT and 3-T whole-body MRI in the detection of malignancy in treated oropharyngeal and hypopharyngeal carcinoma. **Eur J Nucl Med Mol Imaging**. 2011; 38(6):996-1008.
88. Chang YT, Wu CC*, Shyr YM, Chen TC, Hwang TL, Yeh TS, **Chang KP**, Liu HP, Liu YL, Tsai MH, Chang YS, Yu JS*. Secretome-based identification of ULBP2 as a novel serum marker for pancreatic cancer detection. **PLoS One**. 2011; 6(5):e20029.
89. Tse KP, Su WH, Yang ML, Cheng HY, Tsang NM, **Chang KP**, Hao SP, Shugart YY, Chang YS*. A gender-specific association of CNV at 6p21.3 with NPC susceptibility. **Hum Mol Genet**. 2011; 33(6):886-97.
90. Tse KP, Wu CS, Hsueh C, **Chang KP**, Hao SP, Chang YS, Tsang NM*. The Relationship between Secretory Leukocyte Protease Inhibitor Expression and Epstein-Barr Virus Status among Patients with Nasopharyngeal Carcinoma. **Anticancer Res**. 2012; 32(4):1299-307.
91. Hsu CL, **Chang KP**, Lin CY, Chang HK, Wang CH, Lin TL, Liao CT, Tsang NM, Lee LY, Chan SC, Ng SH, Li HP, Chang YS, Wang HM*. Plasma EBV DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma. **Head Neck**. 2012; 34(8):1064-70.
92. Pai PC, Chuang CC, Tseng CK, Tsang NM*, **Chang KP**, Yen TC, Liao CT, Hong JH, Chang JT. Impact of pretreatment body mass index on patients with head-and-neck cancer treated with radiation. **Int J Radiat Oncol Biol Phys**. 2012; 83(1):e93-e100.
93. Liu HP, Chen CC, Wu CC, Huang YC, Liu SC, Liang Y, **Chang KP**, Chang YS*. Epstein-Barr virus-encoded LMP1 interacts with FGD4 to activate Cdc42 and thereby promote migration of nasopharyngeal carcinoma cells. **PLoS Pathog**. 2012; 8(5):e1002690.

94. Tsai CH, **Chang KP**, Hung SY, Chen WF, Cheng MH, Kao HK*. Postoperative morbidity in head and neck cancer ablative surgery followed by microsurgical free tissue transfer in the elder. **Oral Oncol.** 2012; 48(9):811-16.
95. Hsu WL, Tse KP, Liang S, Chien YC, Su WH, Yu KJ, Cheng YJ, Tsang NM, Hsu MM, **Chang KP**, Chen IH, Chen TI, Yang CS, Goldstein AM, Chen CJ, Chang YS*, Hildesheim A. Evaluation of Human Leukocyte Antigen-A (HLA-A), Other Non-HLA Markers on Chromosome 6p21 and Risk of Nasopharyngeal Carcinoma. **PLoS One.** 2012; 7(8):e42767.
96. Chen LC, Wang LJ, Tsang NM, Ojcius DM, Chen CC, Ouyang CN, Hsueh C, Liang Y, **Chang KP**, Chen CC, Chang YS*. Tumour inflammasome-derived IL-1 β recruits neutrophils and improves local recurrence-free survival in EBV-induced nasopharyngeal carcinoma. **EMBO Mol Med.** 2012; 4(12):1276-93.
97. Huang YH, Chen JL, Yang SH, Liu GH, **Chang KP**, Tsang NM*. Influence of Chinese medicine on weight loss and quality of life during radiotherapy in head and neck cancer. **Integr Cancer Ther.** 2013; 12(1):41-9.
98. Liao CT, Lee LY, Hsueh C, Lin CY, Fan KH, Wang HM, Ng SH, Lin CH, Tsao CK, Chen IH, **Chang KP**, Huang SF, Kang CJ, Fang KH, Wang YC, Chang YL, Huang YC, Tsai CY, Yen TC*. Comparative outcomes in oral cavity cancer with resected pT4a and pT4b. **Oral Oncol.** 2013; 49(3): 230-6.
99. Chen WF, **Chang KP**, Chen CH, Shyu VB, Kao HK*. Outcomes of anterolateral thigh flap reconstruction for salvage laryngopharyngectomy for hypopharyngeal cancer after concurrent chemoradiotherapy. **PLoS One.** 2013; 8(1): e53985.
100. Hsu CL, Chan SC, **Chang KP**, Lin TL, Lin CY, Hsieh CH, Huang SF, Tsang NM, Lee LY, Ng SH, Wang HM*. Clinical scenario of EBV DNA follow-up in patients of treated localized nasopharyngeal carcinoma. **Oral Oncol.** 2013; 49(6):620-5.
101. Chan SC, Kuo WH, Wang HM, Chang JT, Lin CY, Ng SH, Hsu CL, **Chang KP**, Liao CT, Lin YJ, Yen TC*. Prognostic implications of post-therapy 18F-FDG PET in patients with locoregionally advanced nasopharyngeal carcinoma treated with

- chemoradiotherapy. **Ann Nucl Med.** 2013; 27(8): 710-9.
102. Lin SJ, **Chang KP**, Hsu CW, Chi LM, Chien KY, Liang Y, Tsai MH, Lin YT, Yu JS*. Low-molecular-mass secretome profiling identifies C-C motif chemokine 5 as a potential plasma biomarker and therapeutic target for nasopharyngeal carcinoma. **J Proteomics.** 2013; 94C: 186-201.
103. Li HP, Peng CC, Cung IC, Huang ST, Chen CC, **Chang KP**, Hsu CL, Chang YS*. Aberrantly hypermethylated homeobox A2 derepresses metalloproteinase-9 through TBP and promotes invasion in nasopharyngeal carcinoma. **Oncotarget.** 2013; 4(11): 2154-65.
104. Liu SC, Tsang NM, Chiang WC, **Chang KP**, Hseuh C, Liang Y, Juang JL, Chow KP, Chang YS*. Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance. **J Clin Invest.** 2013; 123(12): 5269-83.
105. Su WH, Yao Shugart Y, **Chang KP**, Tsang NM, Tse KP, Chang YS*. How genome-wide SNP-SNP interactions relate to nasopharyngeal carcinoma susceptibility. **PLoS One.** 2013; 8(12): e83034.
106. Hsu CY, Yi YH, **Chang KP**, Chang YS, Chen SJ, Chen HC*. The Epstein-Barr virus-encoded microRNA Mir-BART9 promotes tumor metastasis by targeting E-cadherin in nasopharyngeal carcinoma. **PLoS Pathog.** 2014; 10(2): e1003974.